Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Current application and bioavailability of drug-eluting stents.

Escárcega RO, Baker NC, Lipinski MJ, Magalhaes MA, Minha S, Omar AF, Torguson R, Waksman R.

Expert Opin Drug Deliv. 2014 May;11(5):689-709. doi: 10.1517/17425247.2014.888054. Epub 2014 Feb 17. Review.

PMID:
24533457
2.

Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.

Waksman R, Pakala R.

EuroIntervention. 2009 Dec 15;5 Suppl F:F36-42. doi: 10.4244/EIJV5IFA6. Review.

PMID:
22100674
3.

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.

4.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
5.

Current status of drug-eluting stents.

Räber L, Windecker S.

Cardiovasc Ther. 2011 Jun;29(3):176-89. doi: 10.1111/j.1755-5922.2010.00144.x. Epub 2010 Mar 29. Review.

PMID:
20370793
6.

A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

PMID:
19377384
7.

Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW.

J Am Coll Cardiol. 2014 Feb 4;63(4):299-307. doi: 10.1016/j.jacc.2013.09.061. Epub 2013 Nov 6. Review.

8.

The role of drug-eluting stents for the treatment of coronary chronic total occlusions.

Brilakis ES, Kotsia A, Luna M, Garcia S, Abdullah SM, Banerjee S.

Expert Rev Cardiovasc Ther. 2013 Oct;11(10):1349-58. doi: 10.1586/14779072.2013.838142. Review.

PMID:
24138522
9.

Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES).

Ribichini F, Tomai F, Pesarini G, Zivelonghi C, Rognoni A, De Luca G, Boccuzzi G, Presbitero P, Ferrero V, Ghini AS, Marino P, Vassanelli C; CEREA-DES Investigators.

Eur Heart J. 2013 Jun;34(23):1740-8. doi: 10.1093/eurheartj/eht079. Epub 2013 Mar 14.

PMID:
23492671
10.

Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes.

Gorla R, Loffi M, Verna E, Margonato A, Salerno-Uriarte J.

J Cardiovasc Med (Hagerstown). 2014 Jul;15(7):532-42. doi: 10.2459/JCM.0b013e328365c0fc. Review.

PMID:
24922044
11.

Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.

Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.

Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x.

PMID:
22954234
12.

Current drug-eluting stents in complex patients and lesions.

Elezi S, Dibra A, Schömig A, Kastrati A.

Minerva Cardioangiol. 2006 Feb;54(1):5-22. Review.

PMID:
16467738
14.
15.

Recent developments in drug-eluting coronary stents.

Yildiz M, Yildiz BS, Gursoy MO, Akin I.

Cardiovasc Hematol Disord Drug Targets. 2014;14(3):220-4. Review.

PMID:
25174714
16.

Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.

Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F.

Circ Cardiovasc Interv. 2013 Aug;6(4):378-90. doi: 10.1161/CIRCINTERVENTIONS.113.000415. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Interv. 2013 Dec;6(6):e80.

17.

Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW.

J Am Coll Cardiol. 2013 Aug 6;62(6):496-504. doi: 10.1016/j.jacc.2013.05.022. Epub 2013 Jun 7.

18.

Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.

Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ, Mishkel GJ.

Catheter Cardiovasc Interv. 2010 Jan 1;75(1):93-100. doi: 10.1002/ccd.22194.

PMID:
19787803
19.

Prognostic impact of using drug-eluting-stents on outcome and strategy in multivessel PCI: data from the Frankfurt MV-PCI registry.

Schwietz T, Ehrlich JR, De Rosa S, Fichtlscherer S, Schächinger V, Baier G, Laskowski R, Zeiher AM, Spyridopoulos I, Lehmann R.

J Cardiol. 2013 Jan;61(1):38-43. doi: 10.1016/j.jjcc.2012.08.008. Epub 2012 Oct 18.

20.

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.

Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F.

BMJ. 2013 Nov 8;347:f6625. doi: 10.1136/bmj.f6625.

Supplemental Content

Support Center